|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
|
Barinthus Biotherapeutics plc. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
(CUSIP Number) |
Robert Giffen Collins 1901 Ulmerton Road, Suite 400, Clearwater, FL, 33762 8138178035 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
02/03/2026 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
International Generosity Foundation Trust | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
FLORIDA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
2,734,189.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
6.7 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock |
| (b) | Name of Issuer:
Barinthus Biotherapeutics plc. |
| (c) | Address of Issuer's Principal Executive Offices:
20400 CENTURY BLVD, SUITE 210, GERMANTOWN,
MARYLAND
, 20874. |
| Item 2. | Identity and Background |
| (a) | International Generosity Foundation Trust |
| (b) | 1901 Ulmerton Road, Suite 400, Clearwater, Florida 33762, USA |
| (c) | The Reporting Person is a non-profit trust organized under Section 501(c) of the Internal Revenue Code. Its affairs are managed by its trustee. |
| (d) | The Reporting Person has not been convicted in any criminal proceeding during the last five years. |
| (e) | The Reporting Person has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction during the last five years resulting in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws. |
| (f) | United States of America |
| Item 3. | Source and Amount of Funds or Other Consideration |
The securities reported herein were acquired by the Reporting Person through a combination of purchases and transfers.
A portion of the securities was acquired using the working capital of the Reporting Person. The Reporting Person is a non-profit trust generally funded through donations, including donor-advised funds.
The remaining securities were acquired through transfers or contributions to the Reporting Person and were not acquired through the use of funds. | |
| Item 4. | Purpose of Transaction |
The Reporting Person acquired the securities for investment purposes and in connection with its charitable activities.
The Reporting Person may, from time to time, sell or otherwise dispose of some or all of the securities, including to support its charitable purposes, or acquire additional securities, depending on market conditions and other factors.
Except as set forth above, the Reporting Person has no present plans or proposals that relate to or would result in any of the actions described in Items 4(a) through (j) of Schedule 13D. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | Aggregate Number of Shares Owned: 2,734,189
Percentage of Class of Securities Identified: 6.7 |
| (b) | The Reporting Person has sole voting power with respect to 2,734,189 shares, shared voting power with respect to 0 shares, sole dispositive power with respect to 2,734,189 shares, and shared dispositive power with respect to 0 shares. |
| (c) | The Reporting Person has not effected any transactions in the securities of the Issuer during the past 60 days. |
| (d) | No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. |
| (e) | Not applicable |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
The Reporting Person does not have any contracts, arrangements, understandings or relationships (legal or otherwise) with respect to any securities of the Issuer, other than as described in this Schedule 13D. | |
| Item 7. | Material to be Filed as Exhibits. |
None |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|